Wall Street analysts predict that Conatus Pharmaceuticals Inc (NASDAQ:CNAT) will announce sales of $10.25 million for the current fiscal quarter, Zacks Investment Research reports. Six analysts have provided estimates for Conatus Pharmaceuticals’ earnings. The lowest sales estimate is $7.95 million and the highest is $13.00 million. Conatus Pharmaceuticals reported sales of $9.57 million during the same quarter last year, which would suggest a positive year over year growth rate of 7.1%. The business is scheduled to issue its next earnings report on Wednesday, November 7th.
According to Zacks, analysts expect that Conatus Pharmaceuticals will report full year sales of $38.63 million for the current financial year, with estimates ranging from $32.59 million to $47.50 million. For the next fiscal year, analysts expect that the firm will report sales of $46.18 million per share, with estimates ranging from $27.21 million to $75.44 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side analysts that cover Conatus Pharmaceuticals.
Conatus Pharmaceuticals (NASDAQ:CNAT) last announced its quarterly earnings data on Friday, August 3rd. The biotechnology company reported ($0.15) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.20) by $0.05. Conatus Pharmaceuticals had a negative net margin of 48.46% and a negative return on equity of 69.68%. The company had revenue of $8.77 million during the quarter, compared to the consensus estimate of $9.06 million.
Several research analysts recently commented on CNAT shares. ValuEngine lowered shares of Conatus Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Wednesday, April 18th. Zacks Investment Research upgraded shares of Conatus Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, July 4th. Finally, Oppenheimer set a $14.00 price objective on shares of Conatus Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, May 3rd. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Conatus Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $12.50.
NASDAQ CNAT traded down $0.13 during mid-day trading on Friday, hitting $4.05. The company’s stock had a trading volume of 130,575 shares, compared to its average volume of 244,170. Conatus Pharmaceuticals has a 52-week low of $3.22 and a 52-week high of $7.95. The company has a debt-to-equity ratio of 0.68, a quick ratio of 2.35 and a current ratio of 2.35. The firm has a market capitalization of $126.00 million, a price-to-earnings ratio of -6.64 and a beta of 1.23.
Several institutional investors and hedge funds have recently bought and sold shares of CNAT. The Manufacturers Life Insurance Company raised its stake in shares of Conatus Pharmaceuticals by 253.0% during the first quarter. The Manufacturers Life Insurance Company now owns 22,987 shares of the biotechnology company’s stock valued at $135,000 after purchasing an additional 16,476 shares during the period. Stone Ridge Asset Management LLC purchased a new stake in shares of Conatus Pharmaceuticals during the fourth quarter valued at approximately $143,000. Wells Fargo & Company MN raised its stake in shares of Conatus Pharmaceuticals by 77.4% during the fourth quarter. Wells Fargo & Company MN now owns 34,036 shares of the biotechnology company’s stock valued at $157,000 after purchasing an additional 14,848 shares during the period. LMR Partners LLP purchased a new stake in shares of Conatus Pharmaceuticals during the second quarter valued at approximately $311,000. Finally, JPMorgan Chase & Co. raised its stake in shares of Conatus Pharmaceuticals by 1,205.7% during the first quarter. JPMorgan Chase & Co. now owns 74,062 shares of the biotechnology company’s stock valued at $435,000 after purchasing an additional 68,390 shares during the period. Institutional investors own 39.18% of the company’s stock.
Conatus Pharmaceuticals Company Profile
Conatus Pharmaceuticals Inc, a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for patients with portal hypertension; for patients liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function.
Further Reading: Using the New Google Finance Tool
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Conatus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.